Molecular study of CALR gene mutations in children with leukemia hospitalizedin Kerman hospitals

CALR mutation has recently been identified in myeloproliferative neoplasms, but little is known about the occurrence of this mutation in Iran. This study was performed to molecular study of CALR gene mutations in children with leukemia hospitalized in Kerman hospitals.

The present study was an experimental study. In this study, the mutation of calerticulin was evaluated by simple random sampling in 50 children or in the treatment of myeloproliferative malignancies. To determine the mutation, genomic DNA was first extracted from peripheral blood buffer and mutation was determined by polymerase chain reaction with specific allele. The samples were then sequenced. The results were correlated with demographic factors using SPSS software.

1.2% of patients with myeloproliferative neoplasms had CALR mutation. The rate of CALR gene mutation in the study group is comparable with previous reported results.

Therefore, according to WHO criteria, polymerase chain reaction with specific allele can be used to identify this mutation in Iranian patients with suspected myeloproliferative neoplasms.